Already planning for #chest2023! Please submit ideas for sessions, especially with novel educational formats. Submissions are due by Dec 2. A great opportunity to shape this exciting meeting in Hawaii. @CHESTPulmCardio@accpchest
For all CHEST 2022 attendees with an interest in Pulmonary Vascular Disease and/or Cardiovascular Disease come join us at our Network meeting and presentation today at 11:15!! Dr. Soto will be discussing pitfalls in the diagnosis of pulmonary hypertension in the cath lab.
@ogi_gajic@KhannaAshishCCM While important, is focusing on MAP the wrong variable-rather isnβt adequacy of perfusion (cap refill, urine output, lactate, tissue oxygenation) whatβs important though much harder to ascertain.
@OncIDPharmd The conclusions are opposite to the results of their primary outcome. Further, given the early termination and low enrollment the potential for significant harm: excess mortality in addition to increased recurrence cannot be accurately assessed
1/ We just published our full @Cochrane_ACE systematic review and meta-analysis of videolaryngoscopy versus direct laryngoscopy for adults undergoing tracheal intubation.
The full review is here, but first - some of our key takeaways π
https://t.co/HxzXhF83ZB
@Singh011Jaspal While the sense of most of us is that Covid is associated with thrombotic events, the true comparative risk and longer term outcomes remain unclear. Interesting that the ACTIV4B trial was stopped early for futility due to low incidence of events. https://t.co/j6yNJsErQL
Interesting observational study examining impact of early respiratory support in Covid-19 patients. Not randomized, but was propensity matched and larger than many similar studies. Worse outcomes with NIPPV versus high flow, or early IMV (PSILI?). https://t.co/Wg5civnVOW